Document Detail


Myocardial 11C-diacylglycerol accumulation and left ventricular remodeling in patients after myocardial infarction.
MedLine Citation:
PMID:  15809475     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Left ventricular (LV) remodeling after myocardial infarction (MI) is a maladaptive process that increases the risk of heart failure and death. The myocardial phosphoinositide cycle, which is located downstream from several neurohumoral factors, plays a crucial role in LV remodeling. Our animal studies demonstrated that 1-[1-11C]butyryl-2-palmitoyl-rac-glycerol (11C-DAG) can be used to visualize regions with an activated phosphoinositide cycle. Therefore, we examined whether myocardial 11C-DAG accumulation assessed by PET is relevant to LV enlargement and systolic dysfunction in post-MI patients. METHODS: We performed PET with 11C-DAG in 13 post-anteroseptal MI patients and 4 healthy volunteers. We placed regions of interest on the noninfarcted myocardium and calculated the myocardium-to-left atrial (LA) chamber ratio of 11C-DAG accumulation. RESULTS: The myocardium-to-LA chamber ratio of 11C-DAG was significantly higher in the post-MI patients (mean +/- SD, 1.73 +/- 0.35) compared with that of the healthy volunteers (mean +/- SD, 1.25 +/- 0.13; P < 0.05). In the post-MI patients, the myocardium-to-LA chamber ratio of (11)C-DAG was significantly correlated with the LV end-diastolic volume index (r = 0.79, P < 0.01) and the plasma concentration of brain natriuretic peptide (r = 0.85, P < 0.001) and negatively correlated with the LV ejection fraction (r = -0.69, P < 0.01). CONCLUSION: These findings suggest that the myocardial 11C-DAG accumulation assessed by PET is relevant to LV enlargement, LV systolic dysfunction, and humoral activation in post-MI patients. This new imaging strategy based on intracellular signaling may contribute to the assessment and treatment of post-MI patients.
Authors:
Hiroki Otani; Yutaka Kagaya; Yoshio Imahori; Satoshi Yasuda; Ryo Fujii; Masanobu Chida; Shigeto Namiuchi; Morihiko Takeda; Masahito Sakuma; Jun Watanabe; Tatsuo Ido; Hiroshi Nonogi; Kunio Shirato
Related Documents :
12619865 - Differential cytokine expression in myocytes and non-myocytes after myocardial infarcti...
15671615 - Influence of angiotensin-converting enzyme i/d gene polymorphism on the right ventricul...
19933415 - Changes in left ventricular function and remodeling after myocardial infarction in hypo...
17527115 - Ventricular myocardial fat: ct findings and clinical correlates.
3121275 - Encainide. a review of its pharmacological properties and therapeutic efficacy.
9882775 - Comparison of 2 myocardial velocity gradient assessment methods during dobutamine infus...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  46     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2005 Apr 
Date Detail:
Created Date:  2005-04-05     Completed Date:  2005-06-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  553-9     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Female
Glycerides / diagnostic use*,  pharmacokinetics*
Humans
Male
Middle Aged
Myocardial Infarction / complications,  metabolism*,  radionuclide imaging*
Radiopharmaceuticals / diagnostic use,  pharmacokinetics
Reproducibility of Results
Sensitivity and Specificity
Statistics as Topic
Ventricular Dysfunction, Left / etiology,  metabolism*,  radionuclide imaging*
Ventricular Remodeling / physiology*
Chemical
Reg. No./Substance:
0/1-butyryl-2-palmitoyl-rac-glycerol; 0/Glycerides; 0/Radiopharmaceuticals

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ethics manual: fifth edition.
Next Document:  Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA.